Cargando…
Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?
Heart failure (HF) represents the end-stage condition of several structural and functional cardiovascular diseases, characterized by reduced myocardial pump function and increased pressure load. The dysregulation of neurohormonal systems, especially the hyperactivity of the cardiac adrenergic nervou...
Autores principales: | Bencivenga, Leonardo, Palaia, Maria Emiliana, Sepe, Immacolata, Gambino, Giuseppina, Komici, Klara, Cannavo, Alessandro, Femminella, Grazia Daniela, Rengo, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924864/ https://www.ncbi.nlm.nih.gov/pubmed/33669936 http://dx.doi.org/10.3390/cells10020457 |
Ejemplares similares
-
Muscle Ultrasound as Imaging Domain of Frailty
por: Bencivenga, Leonardo, et al.
Publicado: (2022) -
microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases
por: de Lucia, Claudio, et al.
Publicado: (2017) -
Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System
por: Cannavo, Alessandro, et al.
Publicado: (2017) -
Editorial: Post COVID-19 physical performance and functional capacity
por: Komici, Klara, et al.
Publicado: (2022) -
Targeting GRK5 for Treating Chronic Degenerative Diseases
por: Marzano, Federica, et al.
Publicado: (2021)